Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175